The right arthritis medication depends on which type of arthritis you have and how severe it is. For osteoarthritis, treatment usually starts with over-the-counter pain relievers and anti-inflammatory drugs. For rheumatoid arthritis and other inflammatory types, prescription medications that slow the disease itself are the standard of care, often started as soon as the diagnosis is confirmed. Here’s how each category works and what to expect from it.
Over-the-Counter Pain Relievers
For mild to moderate arthritis pain, two types of medication are available without a prescription: acetaminophen (Tylenol) and NSAIDs like ibuprofen (Advil, Motrin) and naproxen (Aleve).
Acetaminophen reduces pain but does nothing for inflammation, which makes it better suited for osteoarthritis where pain is the main problem. The maximum safe dose is 4,000 milligrams per day, though some formulations cap it at 3,000 milligrams. Going over that threshold raises the risk of serious liver damage, especially if you drink alcohol regularly.
Over-the-counter NSAIDs work differently. They block the enzymes that produce inflammatory chemicals called prostaglandins, which reduces both pain and swelling. The OTC dose of ibuprofen is typically 200 to 400 milligrams per dose, while prescription-strength ibuprofen for arthritis can go as high as 800 milligrams four times a day. Naproxen follows a similar pattern: 220 milligrams over the counter versus up to 500 milligrams twice daily by prescription. That dosing gap matters because inflammatory arthritis often requires the higher prescription range to meaningfully reduce joint inflammation.
Oral NSAIDs at Prescription Strength
When over-the-counter doses aren’t enough, prescription NSAIDs are one of the most common next steps. Beyond higher-dose ibuprofen and naproxen, options include diclofenac, meloxicam, piroxicam, and celecoxib (Celebrex). Celecoxib is a COX-2 selective inhibitor, meaning it targets inflammation more precisely and is somewhat gentler on the stomach than older NSAIDs.
That stomach risk is worth understanding. Between 15% and 30% of people who use NSAIDs long-term develop ulcers visible on endoscopy, and 2% to 4% of those ulcers lead to serious complications like bleeding. Overall, NSAIDs raise the risk of upper gastrointestinal problems by two to four times, though COX-2 inhibitors like celecoxib carry a lower risk than non-selective options. Your risk goes up further if you’re over 65, take blood thinners, or have a history of stomach ulcers.
NSAIDs are effective at relieving pain and stiffness, but they don’t slow the progression of inflammatory arthritis. They manage symptoms while other medications do the deeper work.
Topical NSAIDs
If you want anti-inflammatory relief without as much systemic exposure, topical NSAIDs are a solid alternative. Diclofenac gel (Voltaren) is the most widely used and is now available over the counter. You apply it directly to the painful joint, and the drug absorbs through the skin into the tissue underneath.
In head-to-head comparisons, topical and oral NSAIDs show similar effectiveness for both acute and chronic pain. The tradeoff is straightforward: oral NSAIDs cause more gastrointestinal side effects, while topical versions cause more local skin reactions like redness or itching at the application site. For arthritis in accessible joints like the hands and knees, topical NSAIDs are a particularly good fit because the medication can reach the joint without circulating through your entire body.
Corticosteroids
Corticosteroids are powerful anti-inflammatory drugs that can be taken as pills or injected directly into a swollen joint. They work fast, often providing relief within days, which makes them useful during flares or while waiting for slower-acting medications to kick in.
Oral corticosteroids like prednisone are typically prescribed at 5 to 10 milligrams daily for rheumatoid arthritis. Higher doses are sometimes used short-term for severe flares, but the goal is always to taper down as quickly as possible. Long-term use at higher doses increases the risk of bone thinning, weight gain, high blood sugar, and other complications.
Corticosteroid injections deliver the drug straight to the problem joint, which limits body-wide side effects. However, repeated injections into the same joint may damage cartilage over time, so most doctors limit how often they’re given based on the joint, the diagnosis, and how you respond.
Conventional DMARDs
Disease-modifying antirheumatic drugs, or DMARDs, are the backbone of treatment for rheumatoid arthritis and other inflammatory forms. Unlike NSAIDs and corticosteroids, which manage symptoms, DMARDs actually slow or stop the immune system from attacking joint tissue. This is critical because cartilage damage and bone erosions frequently begin within the first two years of disease. Rheumatologists typically start a DMARD as soon as the diagnosis is confirmed, not after waiting to see if milder treatments work.
Methotrexate is the most commonly prescribed DMARD and usually the first one tried. It’s taken once a week, either as a pill or injection. Clinical improvement can appear as early as three to six weeks after starting, though it often takes a few months to see the full effect. Other conventional DMARDs include sulfasalazine, hydroxychloroquine (Plaquenil), and leflunomide. These are sometimes used alone but are often combined with methotrexate for better disease control.
DMARDs require regular blood work to monitor for side effects, particularly on the liver and blood cell counts. The monitoring schedule is usually more frequent when you first start and spaces out once your doctor confirms you’re tolerating the medication well.
Biologic DMARDs
Biologics are a newer class of DMARDs made from living cells. They target specific parts of the immune system rather than suppressing it broadly, which makes them more precise. Most people try a conventional DMARD like methotrexate first, and biologics are added or substituted if the response isn’t adequate.
The largest group of biologics are TNF inhibitors, which block a protein called tumor necrosis factor that drives joint inflammation. These include etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), certolizumab (Cimzia), and golimumab (Simponi). Some are self-injected at home weekly or every two weeks, while others are given through an infusion at a clinic every several weeks.
Other biologics work through different mechanisms. Abatacept (Orencia) interrupts the signaling between certain immune cells. Rituximab (Rituxan) targets a type of immune cell called B cells. Tocilizumab (Actemra) blocks a specific inflammatory messenger called IL-6. If one biologic doesn’t work well or stops working, switching to one with a different mechanism often helps.
Because biologics dial down part of the immune system, they increase susceptibility to infections. You’ll typically be screened for tuberculosis and hepatitis before starting, and you should report any signs of infection to your doctor promptly while on these medications.
JAK Inhibitors
JAK inhibitors are the newest category of arthritis drugs. They’re pills, not injections, which is a practical advantage over biologics. They work by blocking enzymes called Janus kinases inside immune cells. These enzymes are essential for transmitting inflammatory signals from the cell surface to the nucleus, so blocking them interrupts the chain reaction that causes joint damage.
JAK inhibitors are classified as targeted synthetic DMARDs. They’re generally reserved for people with moderate to severe rheumatoid arthritis who haven’t responded well enough to methotrexate or biologics. Like biologics, they suppress part of the immune system and require monitoring for infections and other side effects.
How Treatments Differ by Arthritis Type
Osteoarthritis and rheumatoid arthritis are fundamentally different diseases, and their treatment reflects that. Osteoarthritis is a wear-and-tear condition where cartilage gradually breaks down. Treatment focuses on pain control with acetaminophen, NSAIDs (oral or topical), and occasional corticosteroid injections. There is no DMARD for osteoarthritis because the disease isn’t driven by immune system attacks on the joints.
Rheumatoid arthritis, on the other hand, is an autoimmune disease where the immune system mistakenly attacks joint lining. Here, controlling inflammation early and aggressively with DMARDs, biologics, or JAK inhibitors is essential to prevent permanent joint damage. NSAIDs and corticosteroids play a supporting role for symptom relief, but they’re not sufficient on their own. The goal is remission or at least very low disease activity, and modern treatment achieves that for a significant number of people when started early enough.